GLP-1 drugs provide cardiovascular protection

A new meta-analysis of relevant clinical studies suggests that GLP 1 weight-loss drugs provide protection against heart attacks, strokes and premature death for up to 2.7 years.

The findings appeared on August 30, 2026 in Cardiovascular Diabetology – Endocrinology Reports.

Dr Simon Cork, Senior Lecturer in Physiology at Anglia Ruskin University in Cambridge, UK and lead author, said: “This is the most comprehensive review to date of long term cardiovascular outcome trials for GLP 1 receptor agonists. We know that one of the factors that weighs on people’s minds when considering going onto these drugs is the potential long-term side effects. Our results show that, when taken over a prolonged period of at least one year, these medications do much more than help control blood sugar or weight. They significantly reduce the risk of heart attacks, strokes and premature death in people who are already vulnerable.

The investigators conducted a review and meta-analysis of randomized, placebo-controlled cardiovascular outcome trials evaluating GLP-1RAs in adults at high cardiovascular risk.

Each trial had enrolled ≥ 3,000 subjects with a minimum follow-up of 12 months.

The primary outcome of this meta-analysis was major adverse cardiovascular events (MACE). Secondary outcomes included cardiovascular mortality, all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure, and adverse events.

Eleven trials enrolling a total of 91,490 subjects were included. The mean period of follow-up was 2.7 years.

The investigators reported that GLP-1RA treatment was associated with a significant 13% reduction in MACE compared with placebo. The analysis also showed significant reductions in cardiovascular mortality, all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for heart failure.

“We found the benefits to be consistent across different drugs, trial designs and patient groups. This has important implications for clinical practice and health policy, particularly given cardiovascular disease is the leading cause of death in the UK,” the authors concluded.